watch
Pfizer Inc.

Pfizer Inc.

Sector: Pharmaceutical Preparations Region: NY, United States


: | Santiago Stock Exchange: PFE | New York Stock Exchange: PFE | NASDAQ OMX Stockholm: PFE | Mexican Stock Exchange: PFE | London Stock Exchange: PFZ | XETRA: PFE | SIX Swiss Exchange: PFE


Similar to: BioGaia AB, Ipsen SA, Mast Therapeutics, Inc.

Pfizer, Inc. is a research-based, global biopharmaceutical company. The company's global portfolio includes medicines and vaccines, as well as many of the world's best-known consumer healthcare products. It collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. It operates through four operating segments: Primary Care, Specialty Care and Oncology, Established Products & Emerging Markets, and Consumer Healthcare. The Primary Care segment includes products in therapeutic and disease areas: Alzheimer's disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory and smoking cessation. The Specialty Care and Oncology segment comprises the Specialty Care business unit and the Oncology business unit. The Specialty Care business unit includes products in the following therapeutic and disease areas: anti-infectives, endocrine disorders, hemophilia, inflammation, multiple sclerosis, ophthalmology, pulmonary arterial hypertension, specialty neuroscience and vaccines. The Oncology business unit includes pharmaceutical products addressing oncology and oncology-related illnesses. The Established Products & Emerging Markets segment comprises the Established Products business unit and the Emerging Markets business unit. The Established Products unit includes pharmaceutical products that have lost patent protection or marketing exclusivity in certain countries and/or regions. The Emerging Markets unit includes human prescription pharmaceutical products sold in emerging markets, including Asia, Latin America, Middle East, Africa, Central and Eastern Europe and Turkey. The Consumer Healthcare segment includes non-prescription products in the following therapeutic categories: dietary supplements, pain management, respiratory and personal care. The company was founded by Charles Pfizer and Charles Erhart in 1849 and is headquartered in New York, NY.

Investor Calendar

Latest Media

Warning! Third-party cookies must be enabled to view SlideShare presentations. ×

Having trouble?

Freda Lewis-Hall, MD, Gives Keynote Address at World Orphan Drug Congress USA

On April 10, 2013, Freda Lewis-Hall, MD, Chief Medical Officer of Pfizer, Inc delivered the keynote speech at Terrappin's World Orphan Drug Congress USA 2013 in Washington, D.C.

Pfizer Inc. video

Freda Lewis-Hall, MD, Gives Keynote Address at World Orphan Drug Congress USA

Pfizer Inc. video

Pfizer Receives GBCHealth Business Leadership Award

Pfizer Inc. video

The Next Big Thing In Biotech: Pfizer

Executives

Ian Read, Chairman of the Board and Chief Executive Officer
Ian Read is Chairman of the Board and Chief Executive Officer of Pfizer, one of the world's leading biopharmaceutical companies, which discovers, develops, manufactures and markets a broad portfolio spanning the entire spectrum of human and animal health products.
Previously, he served as Senior Vice President, Pfizer, and Group President of the Worldwide Biopharmaceutical Businesses, which he led from 2006 through December 2010. In that role, he oversaw five global business units — Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets.
Ian began his career with Pfizer in 1978 as an operational auditor. He worked in Latin America through 1995, holding positions in a number of Pfizer's largest, fastest-growing operations, including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. In 1996, Ian was appointed President of Pfizer's International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in 2002. Ian later became accountable for operations in both the Africa/Middle East region and Latin America as well.
Ian received his B.Sc. in chemical engineering from London University Imperial College in 1974. He earned his Chartered Accountants certification from the Institute of Chartered Accountants of England and Wales in 1978. Ian serves on the Boards of PhRMA, Kimberly-Clark, the European Federation of Pharmaceutical Industries and Associations, and the Partnership for New York City.
Frank D'Amelio, Executive Vice President, Chief Financial Officer and Business O
Frank D'Amelio is the Chief Financial Officer of Pfizer, responsible for the both the financial and business operations of the company. Before joining the company in September 2007, he was Senior Executive Vice President of Integration and Chief Administrative Officer of Alcatel-Lucent, responsible for the integration of the combined Alcatel-Lucent, in addition to the supply chain, information technology, real estate, marketing, legal and U.S. labor relations operations of the company.
Prior to the merger of Alcatel and Lucent Technologies in 2006, Frank was the Chief Operating Officer of Lucent Technologies, responsible for leading business operations, including sales, the product groups, the services business, the supply chain, information technology operations and labor relations. In 2001, he was appointed Executive Vice President and Chief Financial Officer of Lucent, where he helped lead the company through one of the most challenging periods in the telecom industry's history and returned the company to profitability.
When Lucent was spun off from AT&T in 1996, Frank helped establish the financial structure of the new company as the CFO of Lucent's Network Systems Business and was a critical member of the team that met with investors around the world during Lucent's initial public offering. After the IPO, he was appointed the Group President of Lucent's Switching Solutions Group, where he led the manufacturing, research and development, marketing and product management of Lucent's multibillion-dollar, global Switching, Access and Application Software businesses.
Born and raised in New Jersey, Frank earned his MBA in Finance from St. John's University and his bachelor's degree in Accounting from St. Peter's College. He started his career in 1979 at Bell Labs, holding a variety of financial, accounting and general management positions, and moved within AT&T, commanding a series of positions with increasing responsibility.
In 2005 and 2006, Frank was ranked among America's top CFOs by Institutional Investor magazine, and in 2002, he was selected one of the top 10 leaders in his field by Treasury & Risk Management magazine.
He serves on the Board of Directors of Humana, Inc., the Independent College Fund of New Jersey and the JPMorgan Chase National Advisory Board.
Mikael Dolsten, President, Worldwide Research and Development
Mikael Dolsten is the President of Worldwide Research and Development, advancing Pfizer's leadership in small molecule science and medicines, as well as its leadership, expertise, and innovation in the areas of biotherapeutics and vaccines. Worldwide R&D combines entrepreneurial Biotech Units with core platforms; Research Units with deep disease area expertise; and broad multi disciplinary scientific expertise to discover innovative therapeutic programs in biotherapeutics, vaccines and small molecules. Mikael is also co-chair of the company's Portfolio Strategy and Investment (PSI) Committee, which governs major pipeline investments and strategic R&D priorities.
Pfizer scientists across WRD apply industry-leading scientific and technological expertise across a range of small molecule and biologic platforms and modalities. In a global network of research laboratories and clinical study sites, Pfizer R&D professionals and business unit colleagues focus on translating deep science into safe and effective drugs to prevent, treat and cure disease.
Mikael oversees all Pfizer research units and biotech units in PharmaTherapeutics and BioTherapeutics: Antibacterials; Cardiovascular, Metabolic & Endocrine Diseases; Internal Medicine; Neuroscience; Oncology; Pain & Sensory Disorders; Regenerative Medicine; Indications Discovery; Inflammation & Immunology; Orphan & Genetic Diseases; Center for Therapeutic Innovation; Vaccine R&D; CovX; Rinat; and Oligonucleotide Therapeutics.
WRD also includes these global science-based groups: Medicinal Chemistry; Drug Safety R&D; Pharmaceutical Sciences; Pharmacokinetics, Dynamics & Metabolism; Comparative Medicine; Clinical Research; Clinical Programs; Development Operations; Development & Strategic Operations; External R&D Innovation; Research Centers of Emphasis; and Asia R&D.
Previously, Mikael was President of BioTherapeutics R&D, responsible for driving Pfizer leadership, expertise, and innovation in biologic medicines and vaccines.
Prior to joining Pfizer in 2009, Mikael was Senior Vice President, Wyeth Inc., and President of Wyeth Research where he led scientists across the U.S., Europe and Asia in the research and development of small molecules, vaccines and protein-based medicines in Inflammation, Women's Health, Neuroscience, Oncology, Infectious Diseases (vaccines, antibiotics), Hemophilia, GI and Musculoskeletal Diseases.
Before joining Wyeth, Mikael served as Executive Vice President within Pharmaceutical Research & Development / Medicine at Boehringer Ingelheim. He led pharmaceutical research in the U.S., Canada, Germany, Italy, Austria and Japan - with programs in respiratory, inflammation / immunology, oncology, virology, cardiovascular, metabolism and CNS. He was a member of the BI corporate management team responsible for all worldwide development projects and licensing opportunities. Mikael's earlier career included research leader positions with AstraZeneca, Pharmacia and Upjohn.
Mikael earned his Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden. He also studied virology and cell biology at the Weizmann Institute in Israel and has been appointed as Adjunct Professor in Immunology at the Medical Faculty in Lund.
In July 2010, Mikael was elected a fellow of the New York Academy of Medicine. He is an appointed Governor of the New York Academy of Sciences. A member of the Science and Regulatory Executive Committee of The Pharmaceutical Research and Manufacturers of America (PhRMA), Mikael also serves on the PhRMA Foundation Board of Directors.
Mikael has published several patents and about 150 articles in international journals with particular contributions in areas such as molecular cell biology, immunology and oncology.

News & Analysis

You may also be interested in: